



**HAL**  
open science

# Evidence of Novel Susceptibility Variants for Prostate Cancer and a Multiancestry Polygenic Risk Score Associated with Aggressive Disease in Men of African Ancestry

Fei Chen, Ravi Madduri, Alex Rodriguez, Burcu Darst, Alisha Chou, Xin Sheng, Anqi Wang, Jiayi Shen, Edward Saunders, Suhm Rhie, et al.

► **To cite this version:**

Fei Chen, Ravi Madduri, Alex Rodriguez, Burcu Darst, Alisha Chou, et al.. Evidence of Novel Susceptibility Variants for Prostate Cancer and a Multiancestry Polygenic Risk Score Associated with Aggressive Disease in Men of African Ancestry. *European Urology*, 2023, 84 (1), pp.13-21. 10.1016/j.eururo.2023.01.022 . hal-04164446

**HAL Id: hal-04164446**

**<https://univ-rennes.hal.science/hal-04164446v1>**

Submitted on 6 Jan 2025

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Published in final edited form as:

*Eur Urol.* 2023 July ; 84(1): 13–21. doi:10.1016/j.eururo.2023.01.022.

## Evidence of Novel Susceptibility Variants for Prostate Cancer and a Multiancestry Polygenic Risk Score Associated with Aggressive Disease in Men of African Ancestry

A full list of authors and affiliations appears at the end of the article.

### Abstract

**Background:** Genetic factors play an important role in prostate cancer (PCa) susceptibility.

**Objective:** To discover common genetic variants contributing to the risk of PCa in men of African ancestry.

**Design, setting, and participants:** We conducted a meta-analysis of ten genome-wide association studies consisting of 19 378 cases and 61 620 controls of African ancestry.

**Outcome measurements and statistical analysis:** Common genotyped and imputed variants were tested for their association with PCa risk. Novel susceptibility loci were identified and incorporated into a multiancestry polygenic risk score (PRS). The PRS was evaluated for associations with PCa risk and disease aggressiveness.

**Results and limitations:** Nine novel susceptibility loci for PCa were identified, of which seven were only found or substantially more common in men of African ancestry, including an African-specific stop-gain variant in the prostate-specific gene *anoctamin 7 (ANO7)*. A multiancestry PRS of 278 risk variants conferred strong associations with PCa risk in African ancestry studies (odds ratios [ORs] >3 and >5 for men in the top PRS decile and percentile, respectively). More

---

\*Corresponding author. 1450 Biggy Street, Los Angeles, CA 90033 USA. Tel. +1-323-442-7755. haiman@usc.edu (C.A. Haiman).

**Author contributions:** Christopher A. Haiman had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

**Study concept and design:** Haiman, Conti.

**Acquisition of data:** Bensen, Ingles, Kittles, Strom, Rybicki, Nemesure, Isaacs, Stanford, Zheng, Sanderson, John, Park, Xu, Y. Wang, Berndt, Huff, Yeboah, Tettey, Lachance, Tang, Rentsch, Cho, McMahon, Biritwum, Adjei, Tay, Truelove, Niwa, Sellers, Yamoah, Murphy, Crawford, Patel, Bush, Aldrich, Cussenot, Petrovics, Cullen, Neslund-Dudas, Stern, Kote-Jarai, Govindasami, Cook, Chokkalingam, Hsing, Goodman, Hoffmann, Drake, Hu, Keaton, Hellwege, Clark, Jalloh, Gueye, Niang, Ogunbiyi, Idowu, Popoola, Adebisi, Aisuodionoe-Shadrach, Ajibola, Jamda, Oluwole, Nwegbu, Adusei, Mante, Darkwa-Abrahams, Mensah, Diop, Van Den Eeden, Blanchet, Fowke, Casey, Hennis, Lubwama, Thompson Jr., Leach, Easton, Preuss, Loos, Gundell, Wan, Mohler, Fontham, Smith, Taylor, Srivastava, Eeles, Carpten, Kibel, Multigner, Parent, Menegaux, Cancel-Tassin, Klein, Andrews, Rebbeck, Brureau, Ambs, Edwards, Watya, Chanock, Witte, Blot.

**Analysis and interpretation of data:** Chen, Madduri, Rodriguez, Darst, Saunders, Rhie, Conti, Haiman.

**Drafting of the manuscript:** Chen, Haiman.

**Critical revision of the manuscript for important intellectual content:** Chen, Haiman, Conti, Darst.

**Statistical analysis:** Chen, Rodriguez, Chou, Sheng, A. Wang, Shen.

**Obtaining funding:** Haiman, Conti, Gaziano, Justice.

**Administrative, technical, or material support:** Madduri, Sheng.

**Supervision:** Haiman.

**Other:** None.

**Publisher's Disclaimer:** This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

importantly, compared with men in the 40–60% PRS category, men in the top PRS decile had a significantly higher risk of aggressive PCa (OR = 1.23, 95% confidence interval = 1.10–1.38,  $p = 4.4 \times 10^{-4}$ ).

**Conclusions:** This study demonstrates the importance of large-scale genetic studies in men of African ancestry for a better understanding of PCa susceptibility in this high-risk population and suggests a potential clinical utility for PRS in differentiating between the risks of developing aggressive and nonaggressive disease in men of African ancestry.

**Patient summary:** In this large genetic study in men of African ancestry, we discovered nine novel prostate cancer (PCa) risk variants. We also showed that a multiancestry polygenic risk score was effective in stratifying PCa risk, and was able to differentiate risk of aggressive and nonaggressive disease.

## Keywords

African ancestry; Aggressive prostate cancer; Polygenic risk score; Prostate cancer; Susceptibility loci

---

## 1. Introduction

Genetic susceptibility plays a major role in prostate cancer (PCa) risk [1–5], with many established risk variants found at a higher frequency in African ancestry men [1,6–11]. While genome-wide association studies (GWASs) of PCa have been focused predominately on men of European ancestry [1–5], smaller GWASs of African ancestry are successful in identifying African ancestry–specific risk variants that are not found in other populations [6,7,9,11,12], underscoring the importance of including greater diversity in genetic studies. Transancestry and ancestry-specific GWASs have also revealed variants that substantially improve risk prediction in non-European ancestry populations and highlighted both shared and ancestry-specific allelic architecture of PCa across populations [1].

To discover PCa risk variants that are important for men of African ancestry, we conducted the largest genetic analysis to date combining GWAS results from ten consortia and biobanks. We also evaluated the performance of a multiancestry polygenic risk score (PRS) composed of known and novel risk variants in association with PCa risk and disease aggressiveness.

## 2. Patients and methods

The GWAS meta-analysis included 19 378 PCa cases and 61 620 controls of African ancestry from the AAPC Consortium [10], ELLIPSE/PRACTICAL Onco-Array Consortium (ELLIPSE) [6], Ghana Prostate Study (Ghana) [13], ProHealth Kaiser GWAS (Kaiser) [14], Electronic Medical Records and Genomics (eMERGE) Network[15], BioVU Biobank [16], BioMe Biobank [17], California and Uganda Prostate Cancer Study (CA UG) [18], VA Million Veteran Program (MVP) [18], and Maryland Prostate Cancer Case-Control Study (NCI-MD) [19]. Of all studies that contributed samples and/or summary statistics, 9011 cases and 50 634 controls from the CA UG, eMERGE, BioVU, BioMe, NCI-MD, and MVP were not part of any previous PCa GWAS (Supplementary Fig. 1). An overview of each

study is provided in Supplementary Table 1, and information on genotyping and imputation is described in Supplementary Table 2 and Supplementary material.

Per-allele odds ratios (ORs) and standard errors were combined in a fixed-effect inverse-variance-weighted meta-analysis. For genome-wide significant variants ( $p < 5.0 \times 10^{-8}$ ), Joint Analysis of Marginal summary statistics (JAM) was used to obtain conditional effects and  $p$  values, conditioning on all known risk variants in the same region [1]. Associations with conditional  $p < 5.0 \times 10^{-8}$  were considered novel. Credible set variants were identified using JAM from all variants within  $\pm 800$  kb of each index variant. The nine novel variants and their 95% credible sets were annotated for putative evidence of biological functionality using publicly available datasets according to the framework described previously [1].

A PRS was constructed by summing variant-specific weighted allelic dosages from 269 known and nine novel risk variants using the multiancestry weights from a previous transancestry GWAS [1]. We also constructed a PRS using the African ancestry-specific effects estimated from African ancestry men (10 367 cases and 10 986 controls) [1]. The PRS association with PCa risk was assessed in six studies included in the GWASs (“discovery sample”) and evaluated for replication in an independent sample from the Men of African Descent and Carcinoma of the Prostate (MADCaP) Network (“replication sample”; Supplementary Table 3) [20,21].

In all studies, PCa was considered aggressive if one or more of the following criteria were met: tumor stage T3/T4, regional lymph node involvement, metastatic disease (M1), Gleason score  $\geq 8.0$ , prostate-specific antigen (PSA) level  $\geq 20$  ng/ml, or PCa as the underlying cause of death. Nonaggressive PCa was defined as men with no aggressive features meeting one or more of the following criteria: Gleason score  $\leq 7.0$ , PSA  $< 20$  ng/ml, and stage  $\leq T2$  (Supplementary Table 3).

We further tested the PRS for an association with PCa risk stratified by age (age  $\leq 55$  vs  $> 55$  yr) and geographic area (African countries vs non-African countries), and with disease aggressiveness. The  $p$  value for heterogeneity was determined using a Q statistic [22]. More details on statistical analysis are provided in the Supplementary material.

### 3. Results

#### 3.1. Novel susceptibility loci

A total of 27 753 840 genotyped and imputed single-nucleotide variants and small insertion/deletion variants with a minor allele frequency (MAF) of  $\geq 1\%$  in African populations were tested for an association with PCa risk. The inflation factor ( $\lambda$ ) was estimated to be 1.12 (Supplementary Fig. 2), which is equivalent to 1.005 for a study with 1000 cases and 1000 controls ( $\lambda_{1,000}$ ) [23].

In the meta-analysis, 3510 variants were genome-wide significant ( $p < 5 \times 10^{-8}$ ; Fig. 1 and Supplementary Fig. 2). These variants are located in 37 known risk regions and two novel risk regions  $> 1.4$  Mb from known risk regions on chromosomes 3q13.31 (rs72960383/*ZBTB20*) and 4q21.1 (rs144842076/-). Within known risk regions, seven novel

associations were detected on 2p21 (rs73923570/*THADA*), 2q37.3 (rs60985508/*ANO7*), 5p15.33 (rs13172201/*TERT*), 14q23.2 (rs114053368/*SYNE2*), 17p13.1 (rs9895704/*CHD3*), 17q11.2 (rs73991216/–), and 20q13.33 (rs150947563/*ZBTB46*; Table 1, and Supplementary Fig. 3 and 4). The associations with these variants remained genome-wide significant in an analysis conditioning on the known risk variants in the same region (Supplementary Table 4).

The minor alleles for five of the nine novel risk variants (MAFs, 12–40%) were positively associated with PCa risk, with per-allele ORs ranging from 1.09 to 1.12 (Table 1). Four of these variants were substantially more common in African ancestry populations than in other populations, with three being rare in European and Asian populations (< 2%; rs73923570, rs60985508, and rs72960383). The major alleles for the other four risk variants (89–98%) were positively associated with PCa risk, of which three variants (rs9895704, rs73991216, and rs150947563) were polymorphic only in African ancestry populations (Table 1). For all novel risk variants except rs144842076, MAFs were greater in men with higher proportions of African ancestry (AFR%; Supplementary Table 5). Only rs144842076 was not associated with African ancestry.

Based on a familial risk estimate for PCa ranging from 2.0 to 3.0, the 278 PCa variants (269 previously known plus nine novel) are estimated to capture 37–59% of the total familial relative risk (FRR). The nine novel risk variants explain 0.83–1.3% of the FRR, accounting for ~2.3% of the FRR explained by the 278 variants (Supplementary Table 6).

For each novel risk variant, a 95% credible set defined potentially causal variants (Supplementary Table 7 and Supplementary Fig. 3). At 2q37.3, the lead variant (rs60985508) introduces a stop-gain in exon 24 of the long isoform of anoctamin 7 (*ANO7*; NP\_001357623.1:pSer860>\*). The association at 14q23 is represented by rs114053368 and comprises a credible set of 20 variants adjacent to the *ESR2* and *SYNE2* genes. This credible set contains three potential enhancer variants (rs17101673, rs8022302, and rs8007874) that intersect varying combinations of AR, CTCF, ERG, FOXA1, GABPA, GATA2, or NKX3.1 transcription factor binding peaks identified through chromatin immunoprecipitation sequencing in PCa cell lines, in addition to chromatin marks indicative of a regulatory element [1]. Similarly, the lead variant rs9896704 at 17p13/*CHD3* and rs59249234 in the credible set may affect the transcription factor binding of AR, CTCF, FOXA1, GATA2, or NKX3.1. The remaining six lead variants included four intronic variants within the genes *THADA*, *ZBTB20*, *TERT*, and *ZBTB46* and two intergenic variants at 4q21.1 and 17q11.2.

### 3.2. PRS association with PCa risk

Of the 269 known PCa risk variants, 246 were polymorphic in African ancestry populations (MAF > 1%), 236 had a directionally consistent association with PCa risk as previously reported, of which 163 were nominally significant ( $p < 0.05$ ) and 35 were genome-wide significant (Supplementary Table 8). The multiancestry PRS of 278 variants conferred a 3.19-fold (95% confidence interval [CI] = 3.00–3.40) risk of PCa for men in the top 10% (90–100% category) and 5.75-fold (95% CI = 5.06–6.53) risk for men in the top 1% (99–100% category), compared with men with an average genetic risk (40–60% category; Table

2 and Supplementary Fig. 5). PRS associations were replicated in an independent sample of African ancestry from the MADCaP Network, with an OR of 3.52 (95% CI = 2.12–5.84) for men in the top 10% and 7.55 (95% CI = 2.42–23.6) for men in the top 1% of the PRS (Table 2 and Supplementary Fig. 5). The OR per 1 standard deviation (SD) increase in PRS was 1.91 (95% CI = 1.87–1.95) in the discovery studies and 1.68 (95% CI = 1.45–1.94) in the replication study (Supplementary Fig. 6). Comparing with the PRS of 269 known risk variants (per SD, OR = 1.87, 95% CI = 1.83–1.91), the inclusion of the nine novel risk variants did not lead to a statistically significant improvement in the PRS associations ( $p$ -heterogeneity = 0.17) [18]. PRS associations with PCa risk in studies from African countries (average AFR% 92–97%) were similar to those from non-African countries (average AFR% 76–79%; Supplementary Table 9 and Supplementary Fig. 6). Similar results were also observed for a PRS based on African ancestry-specific weights (Supplementary Tables 9 and 10). All subsequent PRS analyses were performed using the multiancestry PRS. In the MVP study, adding the PRS to a base model of age and principal components of ancestry led to an increase of 0.148 in the area under the curve (Supplementary Table 11).

The PRS association with PCa risk was stronger in younger men. Compared with men in the 40–60% PRS category, for men in the top PRS decile, the ORs were 4.13 (95% CI = 3.53–4.84) in men aged  $\leq 55$  yr and 2.96 (95% CI = 2.76–3.17) in men  $>55$  yr ( $p$ -heterogeneity =  $1.4 \times 10^{-4}$ ; Supplementary Table 12). The difference in ORs between younger and older men was even greater for those in the top PRS percentile (OR of 8.95 vs 4.76,  $p$ -heterogeneity =  $1.2 \times 10^{-4}$ ). The OR per 1 SD increase in PRS was also greater in men aged  $\leq 55$  yr (OR = 2.19, 95% CI = 2.08–2.30) than in men  $>55$  yr (OR = 1.84, 95% CI = 1.80–1.88,  $p$ -heterogeneity =  $1.1 \times 10^{-9}$ ; Supplementary Fig. 6).

The PRS showed a stronger association with aggressive disease (OR = 3.95, 95% CI = 3.55–4.39) than nonaggressive disease (OR = 3.08, 95% CI = 2.87–3.31) for men in the top PRS decile compared with men in the 40–60% PRS category ( $p$ -heterogeneity =  $1.5 \times 10^{-4}$ ; Supplementary Fig. 2 and Supplementary Table 13). This greater association with aggressive than with nonaggressive disease was similar across individual studies from African and non-African countries (Supplementary Fig. 7 and Supplementary Table 14). Consistent with the case-control analysis, in the case-case analysis, being in the top PRS decile was associated with a 1.23-fold (95% CI = 1.10–1.38,  $p = 4.4 \times 10^{-4}$ ) risk of aggressive PCa compared with the 40–60% PRS category. The ORs per 1 SD increase in PRS in both case-control and case-case analyses supported these positive associations with aggressive PCa (Supplementary Fig. 6 and Supplementary Table 15). In the subgroup analyses by tumor stage, Gleason score, metastasis, and PCa death (see the Supplementary material), the multiancestry PRS was also positively associated with high-grade (Gleason score  $\geq 8$ ), advanced (stage of T3 or T4), metastatic, or fatal disease (Fig. 2 and Supplementary Table 15).

Of the 255 PCa risk variants that are polymorphic (MAF  $\geq 1\%$ ) in African populations, 17 variants were nominally associated ( $p < 0.05$ ) with the risk of aggressive versus nonaggressive disease (Supplementary Table 16). The PCa risk allele of 14 variants was associated with a higher risk of aggressive disease, while the novel variant rs73991216 and two known variants (rs2659051 and rs76765083) at the *KLK3/PSA* locus were inversely



associated with disease aggressiveness (Table 3). Of the 14 variants positively associated with aggressive PCa, the removal of rs72725854 at 8q24 from the PRS led to the largest decrease in the PRS association with aggressive (21.6% decrease in OR,  $p$ -heterogeneity =  $1.6 \times 10^{-3}$ ) and nonaggressive disease (16.2% decrease in OR,  $p$ -heterogeneity =  $6.1 \times 10^{-4}$ ), and a null association with aggressive disease in the case-case analysis ( $p = 0.09$ ; Supplementary Table 17). Removal of each of the other variants had less impact on the PRS association with aggressive and nonaggressive disease, and the positive association with aggressive disease remained nominally significant in the case-case analysis ( $p < 0.03$ ; Supplementary Table 17).

#### 4. Discussion

In the largest genetic study of PCa in African ancestry men, we identified nine novel risk variants, seven of which were at substantially higher frequencies and/or only polymorphic in populations of African ancestry. A PRS comprising the known and novel risk variants was effective in stratifying PCa risk, with replication of the PRS association demonstrated in an independent sample. For men in the top PRS decile, we observed a significantly greater risk of aggressive PCa than nonaggressive disease.

This study highlights the importance of including African ancestry samples in a genetic analysis to reveal susceptibility loci that cannot be discovered without sampling more ancestrally diverse and heterogeneous populations. A notable example is rs60985508 at the *ANO7* risk region on 2q37.3, which creates a premature termination codon (S860X) within the penultimate exon of the *ANO7* long isoform. *ANO7* is a prostate-specific gene shown to be an independent predictor of PCa prognosis, lymph node metastasis, and early biochemical recurrence [24,25]. Previous studies in European populations have identified three *ANO7* variants (rs77559646/R158H, rs77482050/E226\*, and rs76832527/A759T), of which two are rare in African ancestry populations (MAF <1%) [1,2]. Together with I448S in *CHEK2* [6] and X285K in *HOXB13* [12], S860X in *ANO7* represents another example of risk-associated protein-altering variation that is unique to African ancestry men.

Six other novel risk variants were discovered in known susceptibility regions. Chromosome 5p15.33/*TERT* (telomerase reverse transcriptase) is a well-established cancer susceptibility locus where several PCa risk variants have been identified (rs2242652, rs71595003, rs2736098, rs7725218, and rs10069690). The novel intronic variant rs13172201 represents the strongest independent association with PCa risk in this region for African ancestry men. At 2p21, the African ancestry-specific variant rs73923570 is in intron 30 of *THADA* (thyroid adenoma-associated) and in proximity (86–487 kb) to three independent PCa risk signals in the region (rs6738169, rs7591218, and rs28514770). Germline *THADA* variants have been associated with several traits that were linked with PCa risk, such as waist-hip ratio [26], testosterone levels [27], and type 2 diabetes [28,29], with several variants in a moderate to high correlation with known PCa risk variants.

The novel risk variant rs114053368 at 14q23.2 is in intron 79 of *SYNE2* (spectrin repeat containing nuclear envelope protein 2) and ~90 kb from the known East Asian PCa risk variant rs58262369 in the 3'UTR of the *ESR2* (estrogen receptor 2) gene [30].

We also identified a novel intronic variant rs150947563 in *ZBTB46* and *ZBTB46-AS1* at 20q13.33, ~67 kb from a known PCa risk variant (rs1058319). In several studies, overexpression of *ZBTB46* induced by androgen deprivation promoted castration-resistant PCa and neuroendocrine differentiation of PCa [31–33]; however, whether these variants alter the expression or function of *ZBTB46* has not been investigated. The novel variant rs9895704 at 17p13.1 is in intron 11 of the *CHD3* (chromodomain helicase DNA binding protein 3) gene, ~2 kb from a known risk variant (rs28441558). *CHD3* encodes an ATPase subunit of the nucleosome remodeling deacetylase complex that represses the activity of early growth response 1 (EGR1) [34,35], a transcription factor shown to promote PCa metastasis [36,37]. At 17q11.2, the novel lead variant rs73991216 is intergenic, ~29 kb downstream of the gene *RAB11FIP4* and ~200 kb from the known risk variant rs4795646. However, the mechanisms and genes involved are unclear and warrant further investigation.

Two novel PCa risk variants define new susceptibility regions for PCa. The lead variant rs72960383 at 3q13.31 is in intron 1 of the transcription factor gene *ZBTB20* (zinc finger and BTB domain containing 20). *ZBTB20* was included in a nine-gene expression profile identified in prostate tumors that acquired treatment resistance, which was found to be associated with time to biochemical relapse and PCa metastasis [38]. *ZBTB20* was also a *PTEN*-cooperating tumor suppressor gene, co-downregulated with *PTEN* in both primary and metastatic prostate tumor samples, with lower expression associated with a shorter time to recurrence [39,40]. The lead variant rs144842076 at 4q21.1 is an intergenic variant between the *SHROOM3* (~88 kb) and *SEPT11* (~78 kb) genes in a region not previously implicated in PCa.

We constructed the PRS using external weights from a previous transancestry GWAS to mitigate the potential inflation in PRS associations due to the overlapped samples in PRS development and testing. While addition of the nine novel risk variants to the previous 269-variant PRS did not lead to a marked improvement in PRS performance [1], the replication of PRS associations in an independent sample of African ancestry men, and the similar risk associations observed in studies from African and non-African countries, demonstrated the robustness of the multi-ancestry PRS in risk stratification across African populations with varying degrees of admixture. Consistent with previous findings in European and African populations [1,18], the association of the top PRS decile was greater for younger than for older men, which highlights the contribution of genetics in earlier- versus late-onset disease.

Despite greater statistical power in studies of European ancestry (21 919 aggressive and 39 426 nonaggressive cases), the 269-variant PRS was equally associated with aggressive and nonaggressive PCa [1]. Here, we provide the first evidence that a PRS can differentiate between the risks of aggressive and nonaggressive PCa for African ancestry men in the top PRS decile. A significantly higher risk of high-grade, advanced, metastatic, or fatal disease was also observed for men in the top PRS decile. This association was not driven by the greater effect in younger versus older men since age at diagnosis was similar in aggressive and nonaggressive cases across studies. The African-specific variant rs72725854 at 8q24, which accounts for the largest fraction of PCa risk of all variants known to date, made the greatest contribution to the PRS-aggressive disease association. Men of European ancestry



do not harbor this risk variant, which could explain the difficulty in associating the PRS with disease aggressiveness in European populations.

## 5. Conclusions

This study underscores the importance of a large-scale genetic analysis in African ancestry men for a better understanding of PCa susceptibility in this high-risk population. In addition to the discovery of nine novel risk variants, PRS was validated as an effective tool for PCa risk stratification in African ancestry men. Importantly, we found that PRS could distinguish an African ancestry men's risk of developing aggressive versus nonaggressive disease. As the first evidence of this association, future studies are warranted to further validate and characterize this relationship. Risk-stratified screening studies in African ancestry populations are needed to determine the benefits of an earlier and more frequent PSA screening strategy for those at a high genetic risk.

### Data sharing:

The summary statistics, genotype data, and/or relevant covariate information used in this study are deposited in dbGaP (<https://www.ncbi.nlm.nih.gov/gap/>) under accession codes phs001120.v2.p2, phs001391.v1.p1, phs001120.v2.p2, and phs000838.v1.p1. The MVP individual-level data are available to approved VA researchers through standard mechanisms. Full MVP GWAS summary statistics can be found in dbGaP under the MVP accession (phs001672). All analyses were performed using R statistical packages freely available at <https://cran.r-project.org/mirrors.html>. The R code for the PRS association analysis was modified from the code available at [https://github.com/USCmec/Polfus\\_Darst\\_HGGA\\_2021/](https://github.com/USCmec/Polfus_Darst_HGGA_2021/).

### Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

### Authors

Fei Chen<sup>a</sup>, Ravi K. Madduri<sup>b</sup>, Alex A. Rodriguez<sup>b</sup>, Burcu F. Darst<sup>a,c</sup>, Alisha Chou<sup>a</sup>, Xin Sheng<sup>a</sup>, Anqi Wang<sup>a</sup>, Jiayi Shen<sup>a</sup>, Edward J. Saunders<sup>d</sup>, Suhni K. Rhie<sup>e</sup>, Jeannette T. Bensen<sup>f,g</sup>, Sue A. Ingles<sup>a</sup>, Rick A. Kittles<sup>h</sup>, Sara S. Strom<sup>i</sup>, Benjamin A. Rybicki<sup>j</sup>, Barbara Nemesure<sup>k</sup>, William B. Isaacs<sup>l</sup>, Janet L. Stanford<sup>c</sup>, Wei Zheng<sup>m</sup>, Maureen Sanderson<sup>n</sup>, Esther M. John<sup>o</sup>, Jong Y. Park<sup>p</sup>, Jianfeng Xu<sup>q</sup>, Ying Wang<sup>r</sup>, Sonja I. Berndt<sup>s</sup>, Chad D. Huff<sup>i</sup>, Edward D. Yeboah<sup>t</sup>, Yao Tettey<sup>u,v</sup>, Joseph Lachance<sup>w</sup>, Wei Tang<sup>x</sup>, Christopher T. Rentsch<sup>y,z,aa</sup>, Kelly Cho<sup>bb,cc</sup>, Benjamin H. McMahon<sup>dd</sup>, Richard B. Biritwum<sup>v</sup>, Andrew A. Adjei<sup>ee</sup>, Evelyn Tay<sup>v</sup>, Ann Truelove<sup>ff</sup>, Shelley Niwa<sup>ff</sup>, Thomas A. Sellers<sup>p</sup>, Kosj Yamoah<sup>p,gg</sup>, Adam B. Murphy<sup>hh</sup>, Dana C. Crawford<sup>ii</sup>, Alpa V. Patel<sup>r</sup>, William S. Bush<sup>ii</sup>, Melinda C. Aldrich<sup>jj</sup>, Olivier Cussenot<sup>kk,ll</sup>, Gyorgy Petrovics<sup>mm</sup>, Jennifer Cullen<sup>ii,mm</sup>, Christine M. Neslund-Dudas<sup>l</sup>, Mariana C. Stern<sup>a</sup>, Zsofia Kote-Jarai<sup>d</sup>, Koveela Govindasami<sup>d</sup>, Michael B. Cook<sup>s</sup>, Anand P. Chokkalingam<sup>nn</sup>, Ann W. Hsing<sup>o</sup>, Phyllis J. Goodman<sup>oo</sup>, Thomas J. Hoffmann<sup>pp</sup>, Bettina F. Drake<sup>qq</sup>, Jennifer J. Hu<sup>rr</sup>, Jacob M. Keaton<sup>m,ss</sup>,

Jacklyn N. Hellwege<sup>m,tt</sup>, Peter E. Clark<sup>uu</sup>, Mohamed Jalloh<sup>vv</sup>, Serigne M. Gueye<sup>vv</sup>, Lamine Niang<sup>vv</sup>, Olufemi Ogunbiyi<sup>ww</sup>, Michael O. Idowu<sup>ww</sup>, Olufemi Popoola<sup>ww</sup>, Akindele O. Adebiji<sup>ww</sup>, Oseremen I. Aisuodionoe-Shadrach<sup>xx</sup>, Hafees O. Ajibola<sup>xx</sup>, Mustapha A. Jamda<sup>xx</sup>, Olabode P. Oluwole<sup>xx</sup>, Maxwell Nwegbu<sup>xx</sup>, Ben Adusei<sup>yy</sup>, Sunny Mante<sup>yy</sup>, Afua Darkwa-Abrahams<sup>v</sup>, James E. Mensah<sup>v</sup>, Halimatou Diop<sup>zz</sup>, Stephen K. Van Den Eeden<sup>aaa,bbb</sup>, Pascal Blanchet<sup>ccc</sup>, Jay H. Fowke<sup>ddd</sup>, Graham Casey<sup>eee</sup>, Anselm J. Hennis<sup>k</sup>, Alexander Lubwama<sup>fff</sup>, Ian M. Thompson Jr.<sup>ggg</sup>, Robin Leach<sup>hhh</sup>, Douglas F. Easton<sup>iii</sup>, Michael H. Preuss<sup>jjj</sup>, Ruth J. Loos<sup>jjj</sup>, Susan M. Gundell<sup>a</sup>, Peggy Wan<sup>a</sup>, James L. Mohler<sup>g,kkk</sup>, Elizabeth T. Fontham<sup>lll</sup>, Gary J. Smith<sup>kkk</sup>, Jack A. Taylor<sup>mmm,nnn</sup>, Shiv Srivastava<sup>ooo</sup>, Rosaline A. Eeles<sup>d,ppp</sup>, John D. Carpten<sup>qqq</sup>, Adam S. Kibel<sup>rrr</sup>, Luc Multigner<sup>sss</sup>, Marie-Élise Parent<sup>ttt</sup>, Florence Menegaux<sup>uuu,vvv</sup>, Geraldine Cancel-Tassin<sup>kk,ll</sup>, Eric A. Klein<sup>www</sup>, Caroline Andrews<sup>xxx,yyy</sup>, Timothy R. Rebbeck<sup>xxx</sup>, Laurent Brureau<sup>ccc</sup>, Stefan Ambs<sup>x</sup>, Todd L. Edwards<sup>m</sup>, Stephen Watya<sup>fff</sup>, Stephen J. Chanock<sup>s</sup>, John S. Witte<sup>zzz,aaaa</sup>, William J. Blot<sup>m,bbbb</sup>, J. Michael Gaziano<sup>b,b,cccc</sup>, Amy C. Justice<sup>y,z</sup>, David V. Conti<sup>a</sup>, Christopher A. Haiman<sup>a,\*</sup>

## Affiliations

<sup>a</sup>Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA

<sup>b</sup>Argonne National Laboratory, Lemont, IL, USA

<sup>c</sup>Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA

<sup>d</sup>The Institute of Cancer Research, London, UK

<sup>e</sup>Department of Biochemistry and Molecular Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA

<sup>f</sup>Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

<sup>g</sup>Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

<sup>h</sup>Department of Population Sciences, City of Hope Comprehensive Cancer Center, Duarte, CA, USA

<sup>i</sup>Department of Epidemiology, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA

<sup>j</sup>Department of Public Health Sciences, Henry Ford Hospital, Detroit, MI, USA

<sup>k</sup>Department of Family, Population and Preventive Medicine, Stony Brook University, Stony Brook, NY, USA

<sup>l</sup>James Buchanan Brady Urological Institute, Johns Hopkins Hospital and Medical Institution, Baltimore, MD, USA

<sup>m</sup>Division of Epidemiology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA

<sup>n</sup>Department of Family and Community Medicine, Meharry Medical College, Nashville, TN, USA

<sup>o</sup>Department of Medicine, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA

<sup>p</sup>Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, FL, USA

<sup>q</sup>Program for Personalized Cancer Care and Department of Surgery, NorthShore University HealthSystem, Evanston, IL, USA

<sup>r</sup>Department of Population Science, American Cancer Society, Kennesaw, GA, USA

<sup>s</sup>Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD, USA

<sup>t</sup>University of Ghana Medical School, Accra, Ghana

<sup>u</sup>Department of Pathology, University of Ghana, Accra, Ghana

<sup>v</sup>Korle Bu Teaching Hospital, Accra, Ghana

<sup>w</sup>School of Biological Sciences, Georgia Institute of Technology, Atlanta, GA, USA

<sup>x</sup>Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA

<sup>y</sup>Yale School of Medicine, New Haven, CT, USA

<sup>z</sup>VA Connecticut Healthcare System, West Haven, CT, USA

<sup>aa</sup>Faculty of Epidemiology and Population Health, London School of Hygiene & Tropical Medicine, London, UK

<sup>bb</sup>Division of Aging, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA

<sup>cc</sup>VA Boston Healthcare System, Jamaica Plain, MA, USA

<sup>dd</sup>Theoretical Biology Division, Los Alamos National Lab, Los Alamos, NM, USA

<sup>ee</sup>Department of Pathology, University of Ghana Medical School, Accra, Ghana

<sup>ff</sup>Westat, Rockville, MD, USA

<sup>gg</sup>Department of Radiation Oncology, Moffitt Cancer Center, Tampa, FL, USA

<sup>hh</sup>Department of Urology, Northwestern University, Chicago, IL, USA

<sup>ii</sup>Department of Population and Quantitative Health Sciences, Cleveland Institute for Computational Biology, Case Western Reserve University, Cleveland, OH, USA

<sup>jj</sup>Division of Epidemiology, Department of Thoracic Surgery, Vanderbilt University Medical Center, Nashville, TN, USA

<sup>kk</sup>Department of Urology and Predictive Onco-Urology Group, Sorbonne Université, GRC 5 Predictive Onco-Urology, APHP-Sorbonne Université, Paris, France

<sup>ll</sup>CeRePP, Tenon Hospital, Paris, France

<sup>mm</sup>Department of Surgery, Center for Prostate Disease Research, Uniformed Services University of the Health Sciences, Bethesda, MD, USA

<sup>nn</sup>School of Public Health, University of California, Berkeley, Berkeley, CA, USA

<sup>oo</sup>SWOG Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, WA, USA

<sup>pp</sup>Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, USA

<sup>qq</sup>Division of Public Health Sciences, Washington University School of Medicine, St. Louis, MO, USA

<sup>rr</sup>The University of Miami School of Medicine, Sylvester Comprehensive Cancer Center, Miami, FL, USA

<sup>ss</sup>Center for Precision Health Research, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA

<sup>tt</sup>Division of Genetic Medicine, Department of Medicine, Vanderbilt Genetics Institute, Nashville, TN, USA

<sup>uu</sup>Atrium Health/Levine Cancer Institute, Charlotte, NC, USA

<sup>vv</sup>Hôpital Général Idrissa Pouye, Dakar, Senegal

<sup>ww</sup>College of Medicine, University of Ibadan and University College Hospital, Ibadan, Nigeria

<sup>xx</sup>College of Health Sciences, University of Abuja, University of Abuja Teaching Hospital and Cancer Science Center, Abuja, Nigeria

<sup>yy</sup>37 Military Hospital, Accra, Ghana

<sup>zz</sup>Laboratoires Bacteriologie et Virologie, Hôpital Aristide Le Dantec, Dakar, Senegal

<sup>aaa</sup>Division of Research, Kaiser Permanente, Northern California, Oakland, CA, USA

<sup>bbb</sup>Department of Urology, University of California, San Francisco, San Francisco, CA, USA

<sup>ccc</sup>CHU de Pointe-à-Pitre, Univ Antilles, Univ Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail), Pointe-à-Pitre, Guadeloupe, France

<sup>ddd</sup>Department of Preventive Medicine, Division of Epidemiology, The University of Tennessee Health Science Center, Memphis, TN, USA

<sup>eee</sup>Department of Public Health Science, Center for Public Health Genomics, University of Virginia, Charlottesville, VA, USA

<sup>fff</sup>Uro Care, Kampala, Uganda

<sup>ggg</sup>CHRISTUS Santa Rosa Medical Center Hospital, San Antonio, TX, USA

<sup>hhh</sup>Department of Urology, Cancer Therapy and Research Center, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA

<sup>iii</sup>Department of Public Health and Primary Care, Centre for Cancer Genetic Epidemiology, University of Cambridge, Strangeways Research Laboratory, Cambridge, UK

<sup>jjj</sup>The Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA

<sup>kkk</sup>Department of Urology, Roswell Park Cancer Institute, Buffalo, NY, USA

<sup>lll</sup>School of Public Health, Louisiana State University Health Sciences Center, New Orleans, LA, USA

<sup>mmm</sup>Epidemiology Branch, National Institute of Environmental Health Sciences, Research Triangle Park, NC, USA

<sup>nnn</sup>Laboratory of Molecular Carcinogenesis, National Institute of Environmental Health Sciences, Research Triangle Park, NC, USA

<sup>ooo</sup>Department of Biochemistry and Molecular & Cellular Biology, Georgetown University Medical Center, Washington, DC, USA

<sup>ppp</sup>Royal Marsden NHS Foundation Trust, London, UK

<sup>qqq</sup>Department of Translational Genomics, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA

<sup>rrr</sup>Department of Urology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA

<sup>sss</sup>Univ Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail), Rennes, France

<sup>ttt</sup>Epidemiology and Biostatistics Unit, Centre Armand-Frappier Santé Biotechnologie, Institut national de la recherche scientifique, Laval, QC, Canada

<sup>uuu</sup>Cancer & Environment Group, Center for Research in Epidemiology and Population Health (CESP), INSERM, University Paris-Sud, University Paris-Saclay, Villejuif Cédex, France

<sup>vvv</sup>Paris-Sud University, Villejuif Cédex, France

<sup>www</sup>Cleveland Clinic Lerner Research Institute, Cleveland, OH, USA

<sup>xxx</sup>Harvard TH Chan School of Public Health and Division of Population Sciences, Dana Farber Cancer Institute, Boston, MA, USA

yyyGlickman Urological & Kidney Institute, Cleveland, OH, USA

zzzDepartment of Epidemiology and Population Health, Stanford University, Stanford, CA, USA

aaaaStanford Cancer Institute, Stanford University, Stanford, CA, USA

bbbbInternational Epidemiology Institute, Rockville, MD, USA

ccccVA Boston Healthcare System, Boston, MA, USA

## Funding/Support and role of the sponsor

This work was supported by the National Cancer Institute at the National Institutes of Health (grant numbers U19CA148537 to Christopher A. Haiman, U19CA214253 to Christopher A. Haiman, and R01CA257328 to Christopher A. Haiman, and T32CA229110 to Fei Chen), the Prostate Cancer Foundation (20CHAS03 to Christopher A. Haiman), and the Million Veteran Program-MVP017. This research is based on data from the Million Veteran Program, Office of Research and Development, Veterans Health Administration, and was supported by award MVP017. This publication does not represent the views of the Department of Veteran Affairs or the United States Government. The North Carolina-Louisiana Prostate Cancer Project (PCaP) is carried out as a collaborative study supported by the Department of Defense contract DAMD 17-03-2-0052.

### Financial disclosures:

Christopher A. Haiman certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: None.


## References

- [1]. Conti DV, Darst BF, Moss LC, et al. Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. *Nat Genet* 2021;53:65–75. [PubMed: 33398198]
- [2]. Dadaev T, Saunders EJ, Newcombe PJ, et al. Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants. *Nat Commun* 2018;9:2256. [PubMed: 29892050]
- [3]. Schumacher FR, Al Olama AA, Berndt SI, et al. Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. *Nat Genet* 2018;50:928–36. [PubMed: 29892016]
- [4]. Eeles RA, Olama AAA, Benlloch S, et al. Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. *Nat Genet* 2013;45:385–91, 391e1–2. [PubMed: 23535732]
- [5]. Al Olama AA, Kote-Jarai Z, Berndt SI, et al. A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer. *Nat Genet* 2014;46:1103–9. [PubMed: 25217961]
- [6]. Conti DV, Wang K, Sheng X, et al. Two novel susceptibility loci for prostate cancer in men of African ancestry. *JNCI J Natl Cancer Inst* 2017;109:djx084.
- [7]. Haiman CA, Chen GK, Blot WJ, et al. Genome-wide association study of prostate cancer in men of African ancestry identifies a susceptibility locus at 17q21. *Nat Genet* 2011;43:570–3. [PubMed: 21602798]
- [8]. Haiman CA, Chen GK, Blot WJ, et al. Characterizing genetic risk at known prostate cancer susceptibility loci in African Americans. *PLoS Genet* 2011;7:e1001387.
- [9]. Darst BF, Wan P, Sheng X, et al. A germline variant at 8q24 contributes to familial clustering of prostate cancer in men of African ancestry. *Eur Urol* 2020;78:316–20. [PubMed: 32409115]
- [10]. Han Y, Rand KA, Hazelett DJ, et al. Prostate cancer susceptibility in men of African ancestry at 8q24. *JNCI J Natl Cancer Inst* 2016;108:djv431.




- [11]. Haiman CA, Patterson N, Freedman ML, et al. Multiple regions within 8q24 independently affect risk for prostate cancer. *Nat Genet* 2007;39:638–44. [PubMed: 17401364]
- [12]. Darst BF, Hughley R, Pfennig A, et al. A rare germline HOXB13 variant contributes to risk of prostate cancer in men of African ancestry. *Eur Urol* 2022;81:458–62. [PubMed: 35031163]
- [13]. Cook MB, Wang Z, Yeboah ED, et al. A genome-wide association study of prostate cancer in West African men. *Hum Genet* 2014;133:509–21. [PubMed: 24185611]
- [14]. Hoffmann TJ, Van Den Eeden SK, Sakoda LC, et al. A large multiethnic genome-wide association study of prostate cancer identifies novel risk variants and substantial ethnic differences. *Cancer Discov* 2015;5:878–91. [PubMed: 26034056]
- [15]. McCarty CA, Chisholm RL, Chute CG, et al. The eMERGE network: a consortium of biorepositories linked to electronic medical records data for conducting genomic studies. *BMC Med Genomics* 2011;4:13. [PubMed: 21269473]
- [16]. Roden DM, Pulley JM, Basford MA, et al. Development of a large-scale de-identified DNA biobank to enable personalized medicine. *Clin Pharmacol Ther* 2008;84:362–9. [PubMed: 18500243]
- [17]. Tayo BO, Teil M, Tong L, et al. Genetic background of patients from a university medical center in Manhattan: implications for personalized medicine. *PLoS One* 2011;6:e19166.
- [18]. Chen F, Darst BF, Madduri RK, et al. Validation of a multi-ancestry polygenic risk score and age-specific risks of prostate cancer: a meta-analysis within diverse populations. *ELife* 2022;11:e78304.
- [19]. Smith CJ, Dorsey TH, Tang W, Jordan SV, Loffredo CA, Ambs S. Aspirin use reduces the risk of aggressive prostate cancer and disease recurrence in African-American men. *Cancer Epidemiol Biomark Prev* 2017;26:845–53.
- [20]. Andrews C, Fortier B, Hayward A, et al. Development, evaluation, and implementation of a Pan-African cancer research network: men of African descent and carcinoma of the prostate. *J Glob Oncol* 2018;4:1–14.
- [21]. Harlemon M, Ajayi O, Kachambwa P, et al. A custom genotyping array reveals population-level heterogeneity for the genetic risks of prostate cancer and other cancers in Africa. *Cancer Res* 2020;80:2956–66. [PubMed: 32393663]
- [22]. Schwarzer G, Carpenter JR, Rücker G, editors. *Meta-analysis: fixed effect vs. random effects*. R, Cham: Springer International Publishing; 2015, p. 21–53.
- [23]. Freedman ML, Reich D, Penney KL, et al. Assessing the impact of population stratification on genetic association studies. *Nat Genet* 2004;36:388–93. [PubMed: 15052270]
- [24]. Marx A, Koopmann L, Höflmayer D, et al. Reduced anoctamin 7 (ANO7) expression is a strong and independent predictor of poor prognosis in prostate cancer. *Cancer Biol Med* 2021;18:245–55. [PubMed: 33628598]
- [25]. Mohsenzadegan M, Madjd Z, Asgari M, et al. Reduced expression of NGEF is associated with high-grade prostate cancers: a tissue microarray analysis. *Cancer Immunol Immunother CII* 2013;62:1609–18. [PubMed: 23955683]
- [26]. Pulit SL, Stoneman C, Morris AP, et al. Meta-analysis of genome-wide association studies for body fat distribution in 694 649 individuals of European ancestry. *Hum Mol Genet* 2019;28:166–74. [PubMed: 30239722]
- [27]. Sinnott-Armstrong N, Tanigawa Y, Amar D, et al. Genetics of 35 blood and urine biomarkers in the UK Biobank. *Nat Genet* 2021;53:185–94. [PubMed: 33462484]
- [28]. Sakaue S, Kanai M, Tanigawa Y, et al. A cross-population atlas of genetic associations for 220 human phenotypes. *Nat Genet* 2021;53:1415–24. [PubMed: 34594039]
- [29]. Ray D, Chatterjee N. A powerful method for pleiotropic analysis under composite null hypothesis identifies novel shared loci between Type 2 diabetes and prostate cancer. *PLoS Genet* 2020;16:e1009218.
- [30]. Wang M, Takahashi A, Liu F, et al. Large-scale association analysis in Asians identifies new susceptibility loci for prostate cancer. *Nat Commun* 2015;6:8469. [PubMed: 26443449]
- [31]. Chen W-Y, Zeng T, Wen Y-C, et al. Androgen deprivation-induced ZBTB46-PTGS1 signaling promotes neuroendocrine differentiation of prostate cancer. *Cancer Lett* 2019;440–1:35–46.

- [32]. Liu Y-N, Niu S, Chen W-Y, et al. Leukemia inhibitory factor promotes castration-resistant prostate cancer and neuroendocrine differentiation by activated ZBTB46. *Clin Cancer Res* 2019;25:4128–40. [PubMed: 30962287]
- [33]. Chen W-Y, Wen Y-C, Lin S-R, et al. Nerve growth factor interacts with CHRM4 and promotes neuroendocrine differentiation of prostate cancer and castration resistance. *Commun Biol* 2021;4:22. [PubMed: 33398073]
- [34]. Srinivasan R, Mager GM, Ward RM, Mayer J, Svaren J. NAB2 represses transcription by interacting with the CHD4 subunit of the nucleosome remodeling and deacetylase (NuRD) complex. *J Biol Chem* 2006;281:15129–37. [PubMed: 16574654]
- [35]. Giles KA, Taberlay PC. Mutations in chromatin remodeling factors. In: Boffetta P, Hainaut P, editors. *Encyclopedia of Cancer*. ed. 3. Oxford, UK: Academic Press; 2019, p. 511–27.
- [36]. Adamson ED, Mercola D. Egr1 transcription factor: multiple roles in prostate tumor cell growth and survival. *Tumor Biol* 2002;23:93–102.
- [37]. Li L, Ameri AH, Wang S, et al. EGR1 regulates angiogenic and osteoclastogenic factors in prostate cancer and promotes metastasis. *Oncogene* 2019;38:6241–55. [PubMed: 31312026]
- [38]. Stelloo S, Nevedomskaya E, van der Poel HG, et al. Androgen receptor profiling predicts prostate cancer outcome. *EMBO Mol Med* 2015;7:1450–64. [PubMed: 26412853]
- [39]. de la Rosa J, Weber J, Rad R, Bradley A, Cadiñanos J. Disentangling PTEN-cooperating tumor suppressor gene networks in cancer. *Mol Cell Oncol* 2017;4:e1325550.
- [40]. de la Rosa J, Weber J, Friedrich MJ, et al. A single-copy Sleeping Beauty transposon mutagenesis screen identifies new PTEN-cooperating tumor suppressor genes. *Nat Genet* 2017;49:730–41. [PubMed: 28319090]



**Fig. 1 –.** Genome-wide associations with prostate cancer risk. The association for each variant was estimated in each study/consortium and meta-analyzed across studies using a fixed-effect inverse-variance-weighted method. The nine novel association signals are highlighted in orange. The known risk associations are not shown in this plot. The dash line represents the genome-wide significance at  $p < 5 \times 10^{-8}$ .



**Fig. 2 -.**

Association of the multiancestry PRS with aggressive and nonaggressive forms of prostate cancer. Association was assessed comparing prostate cancer cases by Gleason score, tumor stage, and metastatic or fatal prostate cancer with controls. Results were obtained from each individual study and then meta-analyzed across studies. The *x* axis indicates the PRS category. The *y* axis indicates the ORs, with error bars representing the 95% CIs for each PRS category compared with the 40–60% PRS category. The dotted horizontal line corresponds to an OR of 1. ORs and 95% CIs for each PRS decile and/or strata are provided in Supplementary Tables 13 and 15. CI = confidence interval; OR = odds ratio; PRS = polygenic risk score.

**Table 1 –**

Nine novel risk regions/variants associated with prostate cancer in men of African ancestry

rsID <sup>a</sup>	Chromosomal position	Alleles <sup>b</sup>	Nearest gene (consequence)	RAF <sup>c</sup>	RAF in 1KG (AFR, EUR, EAS) <sup>d</sup>	OR	95% CI	<i>p</i> value <sup>e</sup>
rs73923570 <sup>f</sup>	2:43551893 (2p21)	G/A	<i>THADA</i> (intron)	0.12	0.13, 0, 0	1.12	1.08–1.17	1.46 × 10 <sup>-8</sup>
rs60985508 <sup>f</sup>	2:242163365 (2q37.3)	T/TCA	<i>ANO7</i> (stop-gained)	0.31	0.34, <0.01, 0	1.11	1.08–1.15	1.48 × 10 <sup>-13</sup>
rs72960383	3:114732510 (3q13.31)	A/T	<i>ZBTB20</i> (intron)	0.33	0.40, 0.02, <0.01	1.09	1.06–1.12	5.46 × 10 <sup>-9</sup>
rs144842076	4:77792911 (4q21.1)	C/T	–(intergenic)	0.97	0.98, 0.95, 1.00	1.25	1.16–1.35	1.12 × 10 <sup>-8</sup>
rs13172201 <sup>f</sup>	5:1271661 (5p15.33)	C/T	<i>TERT</i> (intron)	0.40	0.45, 0.24, 0.86	1.10	1.07–1.13	2.36 × 10 <sup>-11</sup>
rs114053368 <sup>f</sup>	14:64606132 (14q23.2)	T/A	<i>SYNE2</i> (intron)	0.20	0.24, 0.06, <0.01	1.12	1.08–1.16	7.07 × 10 <sup>-12</sup>
rs9895704 <sup>f</sup>	17:7801082 (17p13.1)	T/C	<i>CHD3</i> (intron)	0.89	0.88, 1.00, 1.00	1.13	1.08–1.18	9.80 × 10 <sup>-9</sup>
rs73991216 <sup>f</sup>	17:29893888 (17q11.2)	G/A	–(intergenic)	0.89	0.86, 1.00, 1.00	1.19	1.14–1.24	5.34 × 10 <sup>-14</sup>
rs150947563 <sup>f</sup>	20:62441171 (20q13.33)	C/T	<i>ZBTB46</i> (intron)	0.98	0.98, 1.00, 1.00	1.47	1.31–1.66	3.24 × 10 <sup>-10</sup>

CI = confidence interval; OR = odds ratio; RAF = risk allele frequency.

<sup>a</sup>Only the most significant variant defining each association signal was reported.<sup>b</sup>Prostate cancer risk allele/other allele.<sup>c</sup>Weighted mean of RAF estimated in controls across individual African ancestry studies in the meta-analysis.<sup>d</sup>Risk allele frequency in 1000 Genomes Project (1KG) African (AFR), European (EUR), and East Asian (EAS) populations.<sup>e</sup>The *p* value from the fixed-effect inverse-variance-weighted meta-analysis.<sup>f</sup>Variant within ± 800 kb of a known risk variant reported by Conti et al [1].

**Table 2 –**

Association of PRS with prostate cancer risk in men of African ancestry

PRS category <sup>a</sup>	Discovery samples <sup>b</sup> 18 018 cases, 64 034 controls				Replication samples <sup>c</sup> 405 cases, 396 controls			
	Controls	Cases	OR (95% CI)	<i>p</i> value	Controls	Cases	OR (95% CI)	<i>p</i> value
(0–10%)	6407	493	0.33 (0.29–0.37)	$7.49 \times 10^{-93}$	40	15	0.53 (0.26–1.06)	0.07
(10–20%)	6402	780	0.51 (0.47–0.56)	$4.83 \times 10^{-45}$	40	22	0.71 (0.37–1.33)	0.3
(20–30%)	6403	916	0.62 (0.56–0.67)	$3.26 \times 10^{-27}$	39	18	0.57 (0.30–1.12)	0.10
(30–40%)	6402	1024	0.68 (0.63–0.74)	$1.53 \times 10^{-18}$	40	38	1.19 (0.67–2.10)	0.6
(40–60%)	12 806	2960	1.00 (Reference)		79	62	1.00 (Reference)	
(60–70%)	6402	1901	1.28 (1.19–1.38)	$3.12 \times 10^{-11}$	39	40	1.36 (0.77–2.40)	0.3
(70–80%)	6403	2271	1.52 (1.41–1.63)	$9.24 \times 10^{-31}$	40	46	1.53 (0.88–2.66)	0.14
(80–90%)	6402	2867	1.94 (1.81–2.07)	$3.84 \times 10^{-81}$	39	63	2.13 (1.25–3.64)	$5.52 \times 10^{-3}$
(90–100%)	6407	4806	3.19 (3.00–3.40)	$1.22 \times 10^{-281}$	40	101	3.52 (2.12–5.84)	$1.12 \times 10^{-6}$
(99–100%) <sup>d</sup>	643	870	5.75 (5.06–6.53)	$4.30 \times 10^{-160}$	4	21	7.55 (2.42–23.6)	$5.02 \times 10^{-4}$

CI = confidence interval; GWAS = genome-wide association study; OR = odds ratios; PRS = polygenic risk score.

<sup>a</sup> PRS was constructed from the 269 known prostate cancer risk variants and the nine novel variants, weighted by the multi-ancestry effects from the previous trans-ancestry prostate cancer GWAS. PRS percentile categories were based on observed distribution in controls.

<sup>b</sup> Discovery samples included men of African ancestry from the AAPC Consortium, the ELLPSE OncoArray Consortium, the California and Uganda Prostate Cancer Study, the Ghana Prostate Study, the NCI-Maryland Prostate Cancer Case-Control Study, and the Million Veteran Program. ORs and 95% CIs were estimated in logistic regression analysis adjusting for age, substudy (if applicable), and up to ten principal components in each study/consortium, and meta-analyzed across the studies using a fixed-effect inverse-variance-weighted method.

<sup>c</sup> Replication samples were from the Men of African Descent and Carcinoma of the Prostate (MADCaP) Network, which was not part of any previous prostate cancer GWAS.

<sup>d</sup> A separate analysis was performed to evaluate the PRS association with prostate cancer risk in men with an extremely high genetic risk (99–100%).



**Table 3 –**Prostate cancer risk variants associated with disease aggressiveness in case-case analysis ( $p < 0.05$ )

rsID (Effect/ other allele <sup>a</sup> )	Nearest gene	EAF <sup>b</sup> (AFR, EUR)	Aggressive vs nonaggressive <sup>c</sup>	Gleason 8 vs Gleason 6	Stage T3/T4 vs stage T1/T2	Metastatic vs nonaggressive	Fatal vs nonaggressive	OR (95% CI), $p$ value <sup>d</sup>
rs708723 (C/T)	<i>RAB29</i>	0.83, 0.47	1.09 (1.02–1.17) *	1.09 (1.00–1.18) *	1.10 (0.98–1.23)	1.11 (0.93–1.32)	1.05 (0.85–1.29)	
rs11691517 (T/G)	<i>BCL2L11</i>	0.79, 0.75	1.08 (1.00–1.16) *	0.97 (0.89–1.06)	1.04 (0.92–1.17)	0.99 (0.83–1.19)	1.04 (0.84–1.30)	
rs2293607 (T/C)	<i>TERC</i>	0.96, 0.76	1.16 (1.02–1.32) *	1.02 (0.88–1.19)	1.16 (0.93–1.45)	1.15 (0.83–1.60)	1.00 (0.70–1.41)	
rs13142786 (T/A)	<i>RASSF6</i>	0.59, 0.50	1.08 (1.01–1.14) *	1.07 (1.00–1.15) *	1.07 (0.97–1.18)	1.05 (0.90–1.21)	1.15 (0.96–1.38)	
rs339351 (C/A)	<i>RFX6</i>	0.74, 0.69	1.14 (1.07–1.23) **	1.16 (1.07–1.25) **	1.13 (1.01–1.27) *	1.13 (0.95–1.34)	1.03 (0.84–1.27)	
rs4513875 (T/C)	<i>MADIL1</i>	0.08, 0.40	1.10 (1.00–1.20) *	0.99 (0.89–1.11)	1.07 (0.92–1.24)	0.99 (0.77–1.26)	1.02 (0.79–1.33)	
rs834608 (A/T)	<i>TNS3</i>	0.62, 0.60	1.07 (1.00–1.13) *	1.05 (0.98–1.13)	1.07 (0.97–1.18)	1.01 (0.87–1.16)	1.04 (0.87–1.25)	
rs72725854 (T/A)	–(8q24)	0.08, 0.00	1.14 (1.05–1.25) *	1.25 (1.13–1.39) **	1.09 (0.95–1.26)	1.31 (1.06–1.62) *	1.35 (1.04–1.75) *	
rs72725879 (T/C)	–(8q24)	0.37, 0.20	1.07 (1.00–1.13) *	1.09 (1.02–1.17) *	1.06 (0.96–1.16)	1.24 (1.07–1.43) *	1.01 (0.85–1.21)	
rs68010938 (T/TA)	<i>SLC39A1 3</i>	0.01, 0.29	1.16 (1.02–1.33) *	1.17 (1.00–1.36) *	1.04 (0.83–1.31)	1.28 (0.92–1.80)	1.20 (0.83–1.72)	
rs12785905 (C/G)	<i>KDM2A</i>	0.001, 0.05	1.54 (1.14–2.08) *	1.46 (1.03–2.05) *	1.84 (1.10–3.06) *	0.94 (0.38–2.31)	2.88 (1.44–5.76) *	
rs11228580 (C/T)	<i>MYEOV</i>	0.18, 0.18	1.12 (1.04–1.20) *	1.11 (1.02–1.21) *	1.14 (1.02–1.29) *	1.37 (1.16–1.63) **	1.16 (0.94–1.43)	
rs75823044 (T/C)	<i>IRS2</i>	0.04, 0.00	1.23 (1.05–1.45) *	1.28 (1.05–1.57) *	1.60 (1.27–2.02) **	1.64 (1.09–2.46) *	1.52 (0.97–2.37)	
rs17565772 (G/A)	<i>COX16</i>	0.16, 0.47	1.08 (1.01–1.16) *	1.02 (0.94–1.11)	1.09 (0.98–1.23)	1.07 (0.90–1.27)	1.26 (1.03–1.54) *	
rs73991216 (G/A)	–(17q11.2)	0.86, 1.0 0	0.89 (0.80–0.98) *	0.90 (0.80–1.01)	0.90 (0.76–1.05)	0.78 (0.62–0.99) *	1.00 (0.73–1.37)	
rs2659051 (G/C)	<i>KLK15/K LK3</i>	0.85, 0.79	0.89 (0.82–0.97) *	0.86 (0.78–0.94) *	0.90 (0.79–1.03)	0.97 (0.79–1.18)	0.89 (0.70–1.13)	
rs76765083 (T/G)	<i>KLK3</i>	1.00, 0.93	0.69 (0.53–0.90) *	0.57 (0.41–0.78) **	0.75 (0.46–1.22)	0.42 (0.22–0.81) *	0.90 (0.43–1.85)	

CI = confidence interval; EAF = effect allele frequency; OR = odds ratios; PRS = polygenic risk score; PSA = prostate-specific antigen.

<sup>a</sup>Effect allele was set to be the prostate cancer risk-increasing allele.<sup>b</sup>EAF in 1000 Genomes Project (1KG) African (AFR) and European (EUR) populations.

<sup>c</sup>Cases were considered aggressive if one of the following criteria was met: tumor stage T3/T4, regional lymph node involvement, metastatic disease, Gleason score  $\geq 8$ , PSA  $\geq 20$  ng/ml, or prostate cancer as the underlying cause of death. Cases without any aggressive features and meeting one or more of the following criteria were considered nonaggressive: Gleason score  $\leq 7$ , PSA  $<20$  ng/ml, and stage  $\leq T2$ .

<sup>d</sup>ORs and 95% CIs were estimated in a logistic regression analysis adjusting for age, substudy (if applicable), and up to ten principal components in each study/consortium, and meta-analyzed across the studies using a fixed-effect inverse-variance-weighted method.

\*  
 $p < 0.05$ .

\*\*  
 $p < 0.001$ .

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript